Brexit: EU defines possible Solutions for Northern Ireland
Recommendation

17/18 June 2026
Copenhagen, Denmark
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
The European Commission has published a so-called "balanced package" of measures to address some of the most pressing issues related to the implementation of the Protocol on Ireland and Northern Ireland. With this commitment, the EU tries to find "creative solutions".
This Protocol on Ireland and Northern Ireland does not only cover medicines but also for example chilled meet (for which the grace period now was extended), guide dogs or motor insurance Green Cards. For medicines, the solution involves the "EU changing its own rules so that regulatory compliance functions for medicines authorised by the UK for the Northern Ireland market, in accordance with the Protocol, may be located in Great Britain, subject to specific conditions ensuring that the medicines concerned are not further distributed in the EU Internal Market. The Commission will put forward a legislative proposal in the early autumn to be able to finish the legislative process on time."
Related GMP News
29.05.2026European QP Association Developments January through April 2026
15.04.2026ICH Q9 Training Package updated
01.04.2026New EMA GMP Guidelines in the next three Years
01.04.2026New EMA Guidance: Risk Management for Elemental Impurities in Veterinary Medicinal Products
18.03.2026Sampling in the Focus of the FDA
11.03.2026EU Pharma Package: Final Texts officially published


